Francesco Maria Lavino
Chief Executive Officer at F2G Ltd.
Francesco Maria Lavino active positions
| Companies | Position | Start | End |
|---|---|---|---|
F2G Ltd.
 F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | Director/Board Member | 2021-04-11 | - |
| Chief Executive Officer | 2021-04-11 | - | |
| F2g Inc. | Director/Board Member | - | - |
| President | - | - |
Career history of Francesco Maria Lavino
Former positions of Francesco Maria Lavino
| Companies | Position | Start | End |
|---|---|---|---|
| MERCK & CO., INC. | Corporate Officer/Principal | 2015-08-31 | 2017-06-30 |
| CUBIST PHARMACEUTICALS INC | Sales & Marketing | 2013-11-30 | 2015-08-31 |
| MERCK & CO., INC. | Director/Board Member | 2010-12-31 | 2013-10-31 |
| NABRIVA THERAPEUTICS PLC | Corporate Officer/Principal | 2017-07-09 | - |
Training of Francesco Maria Lavino
| Università degli Studi di Napoli Federico II | Undergraduate Degree |
| SDA Bocconi School of Management | Masters Business Admin |
Statistics
International
| United States | 4 |
| Italy | 3 |
| Ireland | 2 |
Operational
| Director/Board Member | 3 |
| Corporate Officer/Principal | 2 |
| Sales & Marketing | 1 |
Sectoral
| Health Technology | 5 |
| Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 2 |
|---|---|
| NABRIVA THERAPEUTICS PLC | Health Technology |
| MERCK & CO., INC. | Health Technology |
| Private companies | 3 |
|---|---|
Cubist Pharmaceuticals LLC
 Cubist Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Cubist Pharmaceuticals LLC operates as a biopharmaceutical company. It focuses on the research, development and commercialization of pharmaceutical products. The company was founded in 1992 and is headquartered in Lexington, MA. | Health Technology |
F2G Ltd.
F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | Health Technology |
| F2g Inc. |
